Ambulance Victoria launches neuro-inclusion toolkit to help paramedics and patients
He remembers it being a hidden thing that he did not talk about, but it was always there.
Now aged 45 and working as a paramedic, Mr Cleghorn has the words to describe the difficulty he faced: dyslexia.
Reading comes with the territory as a paramedic, but thanks to some adjustments at work, he has been able to manage his dyslexia and establish a thriving career.
For example, he transferred lists of medications to an audio format that he could listen to on the commute, a format that suits his brain far better than reading and re-reading text.
"I was a very good example of how these adjustments could work for someone, and how that person could thrive with those helps along the way," he said.
Ambulance Victoria has launched its first neuro-inclusion toolkit, which sets out what sort of adjustments can help in the workplace.
The aim is to better support neurodivergent patients and staff like Mr Cleghorn.
He said adjustments that could be helpful for neurodivergent staff included allowing decompression time for paramedics in quiet places, or space to do their paperwork in a distraction-free environment after a job.
When it comes to making neurodivergent patients comfortable, he said the toolkit suggested questions paramedics could ask, such as "Would you like the lights dimmed?" or "Would you like the noisy devices turned off?"
"Now that there's more of a spotlight on neurodiversity and disability, we do see that we don't do a fantastic job all the time in those areas," he said.
"Being able to ask questions and make those adjustments to allow people to feel comfortable … enough to be able to answer our questions and allow us to assess them is such a key point."
About 11 per cent of Ambulance Victoria's employees identify as neurodivergent, but it is believed this could be higher due to under-reporting.
Ambulance Victoria Gippsland Two region area manager Warwick Bone said he hoped the toolkit would provide clear support for managers, employees and patients.
"We know around 15 to 20 per cent of people have some sort of neurodivergence, which can include things like autism, ADHD, obsessive compulsive disorder, dyslexia and other neurological differences," he said.
The toolkit includes a community-facing information sheet on the potential sensory impacts inside an ambulance.
"If they're in the back of an ambulance and machines are beeping and buzzing, then we can turn those down if they have sensory overload," Mr Bone said.
"We reinforce that if you do feel overcome with the sensory experience … talk to the paramedic that's with you and explain that you are neurodiverse and we can definitely support [you]."
Amaze chief executive David Tonge said his organisation co-designed the toolkit for Ambulance Victoria after a survey of patients.
"What we heard from the community was they'd had varied experiences in their encounters … but there's often a lot of sensory overload," he said.
"Pulling together the expertise of Ambulance Victoria and the paramedics with lived experience … is the strength of this project."
Mr Cleghorn said when it came to adjusting for disability needs, lived experience was crucial for getting things right.
"I can't think of anything where not getting lived experience hasn't improved the outcome or created a more robust system," he said.
"It's the gold standard."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
22 minutes ago
- News.com.au
One of Australia's most experienced doctors believes combating concussion is ‘years and years' away
One of Australia's leading sports doctors suspects combating the full extent of concussion remains 'years and years' away. Dr Peter Harcourt was inducted into the Sport Australia Hall of Fame on Thursday after 40 years of medical service. He oversaw seven Olympic Games and spent time in the AFL and at Basketball Australia tackling the biggest medical hurdles. Harcourt says concussion remains one of the top challenges in world sport and while Australia's football codes have made progress, 'there's still a long way to go'. 'Concussion is the big one at the moment and I think sport is making some pretty big progress,' Harcourt said. 'Certainly, you can see that in the way the game is being played in AFL and in NRL and other competitions like that. 'I think understanding exactly the full depth of it and the mechanisms of it, prevention, the treatment, there's still a long way to go. 'This is going to take years and years to pull it apart and understand what the risks are and how you actually combat that.' Several AFL players, including premiership stars Jeremy McGovern and Angus Brayshaw, have been medically retired due to concussion in recent seasons. Cronulla Sharks co-captain Dane Finucane also last year retired following advice from medical professionals. Harcourt said the awareness of long-term damage had prompted players and sporting clubs to change the narrative around head knocks. 'There's no holding back organisations these days in terms of tackling something that is really critical for the welfare of their athletes,' he said. 'The way we managed it 40 years ago was it was a self-limiting condition that would fully resolve – that's the way you thought about it. 'These days obviously you don't because you're worried about the long-term risks associated with that sort of trauma. 'I think the culture in the player groups has changed in that they will come forward and tell you when they're not well. 'There's been a lot of awareness. I'm not saying that it wouldn't happen (hiding concussions), but I think it's much less than what might've happened 10-15 years ago.'

News.com.au
3 hours ago
- News.com.au
Health Check: Neuren says the US Rett syndrome market is a case of glass half full
Neuren's US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs 'with immediate effect' Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible patients are yet to try the drug. Neuren's US partner Acadia Pharmaceuticals overnight reported quarterly net sales of US$96.1 million, up 14% year on year. The Nasdaq-listed Acadia says a record number of patients received a shipment, growing for the third consecutive quarter. Acadia holds the global rights to Daybue and pays royalties to Neuren, which initially developed the drug. Affecting boys, Rett syndrome is a rare neurodevelopmental disorder resulting in slow development after the ages of six to 18 months. Acadia has guided to net sales of US$380-405 million, which at the current exchange rate will generate $62-67 million of royalties for Neuren in calendar 2025. Neuren earned $14.7 million in the June quarter, up 16% year on year. By their nature, royalties are pretty much pure profit. More patients – and they're more persistent Acadia says a record 987 patients received Daybue in the quarter, up from 954 in the March quarter. Despite concerns about side effects, 50% of patients persisted after 12 months' treatment. Neuren adds that 70% of active patients have now been on therapy for 12 months or longer. This was up from 65% previously. The company says two-thirds of the 5500 to 5800 diagnosed US patients are yet to try Daybue. The FDA approved the therapy in March 2023 and Acadia expects European assent in the March 2026 quarter. Neuren shares this morning spurted as much as 8%. They've more than doubled since their mid-April trough of $8.60. Investors spoil IDT's golden jubilee Veteran contract drug maker IDT Australia's (ASX:IDT) golden jubilee has been spoiled by a savage share rout, resulting from the news that CEO Paul McDonald would depart 'with immediate effect'. The company also issued a lacklustre trading update, flagging a boost in revenue for the year to June 30, 2025, but a widening loss. A former Pfizer exec, McDonald had been in the job for almost three years. Chairman Mark Simari becomes executive chair while the company searches for a new CEO. IDT says its full-year revenue should come in at $19.9 million, a 40% increase. The company cites an increase in disbursement revenue. This derived from raw material costs and equipment charged to customers at a 'modest' margin. IDT says mainly applying to new contracts, disbursements are a 'positive lead indicator'. IDT also expects a net loss of $7.5 million, compared with a $5.4 million deficit last year. This reflects $1.2 million of bad debts from two customers defaulting on payments. Founded in 1975, IDT has had a convoluted history, including missing out on a government funded Covid vaccine plant at the last minute. These days IDT pursues gene technology, antibody drug conjugates, medical marijuana and psychedelic treatments for mental disorders. The company is in the third year of its five-year strategy, spurred by a board 'refresh' in September 2022. IDT's $30 million worth is backed by the value of the company's Boronia premises in eastern Melbourne. This hard-to-replicate is in the books at a conservative $21 million. We're on track, say drug developers Investors can look forward to a slew of company-making trial results in 2026, according to presenters at this year's Bioshares summit in Hobart. Alzheimer's disease drug developer Actinogen Medical (ASX:ACW) says it's on track to report interim results from its advanced phase IIb/III trial, by January next year. The company is enrolling 220 patients for its Xanamia trial for mild to moderate sufferers, across 15 Australian and 20 US sites. Actinogen's candidate Xanamem targets excess levels of cortisol in the brain – a novel mechanism of action. The company expects to unveil data from the first 100 patients, after 24 weeks' treatment. Final results are expected in late 2026. Stem cell developer Cynata Therapeutics (ASX:CYP) expects to release results of its phase III osteoarthritis (OA) trial between February and April next year. Cynata's mesenchymal stromal cells modulate the immune system and enable tissue repair. The OA program is the most advanced of Cynata's four trials that also cover graft-versus-host disease, diabetic foot ulcers and kidney transplants. Vitiligo is a circa US$500 million market, says Clinuvel The developer of an approved treatment for a rare sun intolerance disorder abbreviated as EPP, Clinuvel Pharmaceuticals (ASX:CUV) is advancing its proposed treatment for the more common vitiligo. The company has fully enrolled its 210 patient phase III trial, with a readout due in the June half. Affecting about 1% of the population, vitiligo is skin discolouration that results from the destruction of pigment-producing cells called melanocytes. The late Michael Jackson was a celebrity sufferer. If the drug gets US Food and Drug Administration (FDA) approval, the company estimates US$490-570 million of revenue in years one and two. Put in context, Clinuvel reported revenue of $35.6 million in the 2024 December half, up 10%. These sales derived from the company's EPP treatment, Scenesse. Doing the numbers on Imricor Broker Canaccord reckons Imricor Medical Systems (ASX:IMR) could be worth more than twice its current valuation – but faces constrained hospital budgets for the time being. In a 60-page appraisal of the cardiac ablation catheter developer, the firm estimates 120 US hospitals could be using the device within five years. Assuming 35% penetration of the ablation procedures, this equates to a $2.50 per share valuation compared with around $1.40 now. 'The big question ... is how quickly can these installs happen,' the firm says. Uniquely, Imricor's catheters are guided in real-time with magnetic resonance imaging – MRI – rather than via x-ray. The procedure is called interventional cardiac magnetic resonance cardiac ablation (ICMR CA). The company initially is focused on the US$12b arrhythmia market. Canaccord believes Imricor is still 12-18 months away from a 'material revenue ramp'. But after that it's off to the races. Imricor has an initial US target market as 120 large academic hospitals, 20 of them high volume. The firm estimates that facilities will install 190 ICMR US labs globally five years post launch. Of these, 100 will be in the US with total revenue of US$250 million. Imricor currently is undertaking a trial aimed at FDA approval for atrial flutter procedures, with a decision by the end of 2026.

News.com.au
3 hours ago
- News.com.au
Indonesian protesters call for Australia to stop sending plastic waste as microplastic found in foetuses
Furious scenes have erupted outside an Australian embassy overseas, with protesters claiming their babies are being 'poisoned'. Environmental activists in the Indonesian city of Surabaya have demanded Australia stops sending plastic waste to Indonesia, arguing the contaminated waste has developed micro plastics in foetuses. Protesters dragged two large dolls in front of the Australian Consulate-General to depict a scene of babies engulfed by contaminated plastic waste, and a mannequin of a pregnant mother. They arrived also with masks, signs and a megaphone relaying their message. 'Australia's plastic waste is poisoning out babies,' one sign read. 'Your plastic lifestyle destroys babies' future,' another read. The news comes as Ecological Observation and Wetland Conservation (ECOTON) recently revealed Australia was the largest exporter of plastic waste to Indonesia between 2020 and 2024, sending more than 2.7 billion kilograms, according to the UN Comtrade Database. It also found more than 60 per cent of paper waste sent from Australia to Indonesia was contaminated either by flexible plastics scrap, multilayer plastic or soiled plastic packaging. Such materials cannot be recycled and end up building up at illegal dump sites. Even more concerning, in late 2014 ECOTON tested more than 80 baby care products and found nearly 60 per cent of them contained microbeads, which are tiny plastics that enter the body through the skin. 'We found that microplastics were already present in the foetus,' one protester said. 'Then our findings show they were in the placenta, meaning these small plastic particles were already able to penetrate the placenta and also the amniotic fluid. 'Now, this can be concerning for the future of this nation's life.' The move aims to put pressure on the Australian government to reconsider how it disposes of plastic waste and the impact on the Indonesian people. It's another push drawing attention to the matter that has become a big talking point Indonesia, with protests becoming almost routine. Protesters organised a similar event last year in July when the 'Your Trash Drowns Us' protest was held in the same spot outside the embassy, demanding the Australian government to stop sending plastic waste that was impacting the environment in East Java. 'I've heard of the concept of Laudato Si' from Pope Francis. Are we going there? Hopefully,' Indonesian environmentalist Prigi Arisandi said. Laudato Si', the then-pope's encyclical from 2015, stressed the international obligation to take care of the environment, with a call for ecological conversion.